(Q47747965)

5 February 2018

title

Reduced bikunin gene expression as a factor of poor prognosis in ovarian carcinoma. (English)

1 reference

5 February 2018

2

Hiroshi Kobayashi

1 reference

5 February 2018

author name string

Yoshiko Tanaka

1

1 reference

5 February 2018

Mika Suzuki

3

1 reference

5 February 2018

Naohiro Kanayama

4

1 reference

5 February 2018

Mitsuaki Suzuki

5

1 reference

5 February 2018

Toru Yamakawa

6

1 reference

5 February 2018

Hideaki Morishita

7

1 reference

5 February 2018

Toshihiko Terao

8

1 reference

5 February 2018

language of work or name

English

0 references

publication date

1 July 2003

1 reference

5 February 2018

published in

Cancer

1 reference

5 February 2018

volume

98

1 reference

5 February 2018

page(s)

424-430

1 reference

5 February 2018

issue

2

1 reference

5 February 2018

Anti-metastatic therapy by urinary trypsin inhibitor in combination with an anti-cancer agent

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11506

Structure and function analysis of urinary trypsin inhibitor (UTI): identification of binding domains and signaling property of UTI by analysis of truncated proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11506

Gene expression of the two heavy chains and one light chain forming the inter-alpha-trypsin-inhibitor in human tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11506

Immunohistochemical distribution of inter-alpha-trypsin inhibitor chains in normal and malignant human lung tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11506

Identification and characterization of the cell-associated binding protein for urinary trypsin inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11506

Suppression of urokinase-type plasminogen activator expression from human ovarian cancer cells by urinary trypsin inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11506

Ovarian cancer: epidemiology, biology, and prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11506

7 January 2021

E-cadherin and urokinase-type plasminogen activator tissue status in gastric carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11506

7 January 2021

The urokinase/urokinase-receptor system and cancer invasion

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11506

7 January 2021

Urinary trypsin inhibitor (UTI) and fragments derived from UTI by limited proteolysis efficiently inhibit tumor cell invasion

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11506

7 January 2021

Effects of urinary trypsin inhibitor on the invasion of reconstituted basement membranes by ovarian cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11506

7 January 2021

Inhibitory effect of a conjugate between human urokinase and urinary trypsin inhibitor on tumor cell invasion in vitro

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11506

7 January 2021

Inhibition of metastasis of Lewis lung carcinoma by urinary trypsin inhibitor in experimental and spontaneous metastasis models

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11506

7 January 2021

A bifunctional hybrid molecule of the amino-terminal fragment of urokinase and domain II of bikunin efficiently inhibits tumor cell invasion and metastasis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11506

7 January 2021

Human myometrial cells in culture express specific binding sites for urinary trypsin inhibitor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11506

7 January 2021

Characterization of binding properties of urinary trypsin inhibitor to cell-associated binding sites on human chondrosarcoma cell line HCS-2/8.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11506

7 January 2021

Can axillary dissection be avoided by improved molecular biological diagnosis?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11506

7 January 2021

Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11506

7 January 2021

EGFR and cancer prognosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11506

7 January 2021

Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11506

7 January 2021

Prognostic impact of stromal cell-derived urokinase-type plasminogen activator in gastric carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11506

7 January 2021

Plasmin/plasminogen system in colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11506

7 January 2021

Expression of ETS-1 is correlated with urokinase-type plasminogen activator and poor prognosis in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11506

7 January 2021

The urokinase-type plasminogen activator system in cancer metastasis: a review

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11506

7 January 2021

Suppression of urokinase expression and invasiveness by urinary trypsin inhibitor is mediated through inhibition of protein kinase C- and MEK/ERK/c-Jun-dependent signaling pathways

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11506

7 January 2021

Identifiers

DOI

10.1002/CNCR.11506

1 reference

5 February 2018

PubMed ID

12872365

1 reference

5 February 2018